Effect of LY293111 in combination with gemcitabine in colonic cancer

Rene Hennig, Xian Zhong Ding, Wei Gang Tong, Richard C. Witt, Borko D. Jovanovic, Thomas E. Adrian

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B4 (LTB4) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option.

Original languageEnglish
Pages (from-to)41-46
Number of pages6
JournalCancer Letters
Issue number1
Publication statusPublished - Jul 8 2004
Externally publishedYes


  • Colon cancer
  • Gemcitabine
  • Heterotopic xenografts
  • LY293111

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Effect of LY293111 in combination with gemcitabine in colonic cancer'. Together they form a unique fingerprint.

Cite this